Occurrence and predictors of adverse events associated with Linezolid in the treatment of patients with MDR-TB

Affiliations

• ¹ Hematology and Medical Oncology Division, Department of Internal Medicine, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; Doctoral Study Program Faculty of Medicine, Universitas Padjadjaran Bandung, West Java, Indonesia.
• ² McGill International TB Centre Montreal Chest Institute, Research Institute of the McGill University Health Centre, Montreal, Canada; Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
• ³ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
• ⁴ Public Health Consulting Group, Lugano, Switzerland.
• ⁵ Division of Respirology and Critical Care, Department of Internal Medicine Dr. Hasan Sadikin General Hospital /Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
• ⁶ Department of Biomedical Science, Division of Pharmacology, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
• ⁷ McGill International TB Centre Montreal Chest Institute, Research Institute of the McGill University Health Centre, Montreal, Canada. Electronic address: dick.menzies@mcgill.ca.